RN
RNXT.US RenovoRx Inc
- Market cap
- USD 46.1M
- P/E
- -
- P/B
- 5.43x
- ROE
- -144.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RNXT.US undervalued?
Graham numberThe Graham number of RenovoRx Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RenovoRx Inc fundamental analysis
No fundamental analysis for RenovoRx Inc yet.
RenovoRx Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
Full company profileRenovoRx Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
RenovoRx Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.0K | 1.12M | 3.38M |
| Gross Profit | - | - | -9.00K | -6.00K | 0.00 | 43.0K | 796K | 2.83M |
| Operating Income | -3.90M | -3.20M | -5.67M | -9.95M | -11.4M | -11.0M | -12.5M | -13.2M |
| EBITDA | -3.84M | -3.21M | -5.48M | -9.94M | -10.1M | -8.81M | -11.2M | -13.4M |
| Net Income | -3.84M | -3.80M | -6.32M | -9.77M | -10.2M | -8.81M | -11.2M | -13.4M |
| EPS | -0.22 | -0.22 | -0.35 | -0.54 | -0.50 | -0.37 | -0.32 | -0.28 |
| Balance Sheet | ||||||||
| Total Assets | 2.27M | 1.91M | 16.3M | 7.27M | 1.47M | 8.12M | 8.10M | 12.4M |
| Total Liabilities | 805K | 16.6M | 938K | 1.10M | 4.47M | 3.64M | 2.67M | 3.15M |
| Shareholders' Equity | 1.47M | -14.7M | 15.3M | 6.16M | -3.00M | 4.48M | 5.42M | 9.28M |
| Cash & Short-term Investments | 2.10M | 1.80M | 15.2M | 6.44M | 1.17M | 7.15M | 7.02M | 10.4M |
| Total Debt | 12.4M | 2.79M | - | - | - | 278K | 212K | 358K |
| Cash Flow | ||||||||
| Operating Cash Flow | -3.35M | -3.53M | -5.92M | -8.81M | -10.3M | -9.13M | -11.0M | -12.2M |
| Capital Expenditure | 15.0K | 15.0K | 15.0K | 0.00 | 0.00 | 12.0K | 2.00K | 208K |
| Free Cash Flow | -3.35M | -3.53M | -5.93M | -8.81M | -10.3M | -9.14M | -11.0M | -12.3M |
| Ratios | ||||||||
| ROE | -262.0% | - | -41.2% | -158.5% | - | -196.8% | -206.0% | -144.8% |
| ROA | -169.1% | -198.4% | -38.8% | -134.5% | -698.0% | -108.6% | -138.0% | -108.1% |
| Net Profit Margin | - | - | - | - | - | -20,497.7% | -994.5% | -397.1% |
| Debt to Equity | 8.46x | - | - | - | - | 0.06x | 0.04x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
RenovoRx Inc dividends
RenovoRx Inc has not paid dividends in the last 7 fiscal years.
Who owns RenovoRx Inc
- Insiders 3.36%
- Institutions 25.46%
- Public & others 71.17%
- Shares outstanding 48.3M
- Free float 42.4M
Top funds holding RNXT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.18M | 2.45% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 200K | 0.41% | -0.38% | Sep 2026 |
| Fidelity Total Market Index | 78.0K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 64.4K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 37.2K | 0.08% | 0.00% | Aug 2026 |
| Vanguard Balanced Index Inv | 29.6K | 0.06% | 0.00% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 19.1K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding RNXT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| AIGH Capital Management, LLC | 4.41M | 9.13% | +18.87% | Jun 2026 |
| Bleichroeder LP | 1.67M | 3.45% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.44M | 2.99% | -0.24% | Jun 2026 |
| Renaissance Technologies Corp | 1.12M | 2.32% | +9,722.36% | Sep 2026 |
| Geode Capital Management, LLC | 424K | 0.88% | +11.11% | Jun 2026 |
| Sontag Advisory LLC | 253K | 0.52% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 240K | 0.50% | +52.20% | Jun 2026 |
| Citadel Advisors Llc | 134K | 0.28% | -42.58% | Jun 2026 |
| Chicago Partners Investment Group LLC | 92.4K | 0.19% | 0.00% | Jun 2026 |
| Northern Trust Corp | 85.2K | 0.18% | +102.10% | Jun 2026 |
| Northwestern Mutual Wealth Management Co | 74.6K | 0.15% | -25.00% | Jun 2026 |
| Caprock Group Inc | 63.9K | 0.13% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 46.4K | 0.10% | +92.23% | Jun 2026 |
| Kestra Advisory Services, LLC | 35.5K | 0.07% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 34.8K | 0.07% | +94.39% | Jun 2026 |
| XTX Topco Ltd | 30.0K | 0.06% | -1.73% | Jun 2026 |
| Clear Creek Investment Mgmt LLC | 29.1K | 0.06% | 0.00% | Jun 2026 |
| State Street Corp | 26.2K | 0.05% | 0.00% | Jun 2026 |
| UBS Group AG | 20.8K | 0.04% | +523.73% | Jun 2026 |
| HighTower Advisors, LLC | 20.0K | 0.04% | 0.00% | Jun 2026 |
RenovoRx Inc company profile
- Company name
- RenovoRx Inc
- Ticker
- RNXT.US
- Exchange
- USA Stocks
- Listed since
- Aug 26, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- 2570 West El Camino Real, Mountain View, CA, United States, 94040
- Phone
- 650 284 4433
- Website
- renovorx.com
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, California.
RenovoRx Inc management
7- Dr. Ramtin Agah M.D.Founder, Executive Chairman & Chief Medical Officer · born 1966
- Mr. Shaun R. BagaiCEO, Secretary & Director · born 1977
- Mr. Ronald B. Kocak CPA, CGMAVP of Finance & Controller · born 1958
- Mr. Mark VollCFO & Principal Accounting Officer · born 1955
- Mr. Tom KellyVice President of Quality & Operations
- Mr. Phil StoctonVice President of Sales & Market Development
- Ms. Leesa GentryChief Clinical Officer · born 1970